- Home
- CERS vs CMPS Comparison
CERS vs CMPS Comparison
Compare CERS & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERS
- CMPS
- Stock Information
- Founded
- CERS 1991
- CMPS 2020
- Country
- CERS United States
- CMPS United Kingdom
- Employees
- CERS N/A
- CMPS N/A
- Industry
- CERS EDP Services
- CMPS Biotechnology: Pharmaceutical Preparations
- Sector
- CERS Technology
- CMPS Health Care
- Exchange
- CERS Nasdaq
- CMPS Nasdaq
- Market Cap
- CERS 324.3M
- CMPS 362.6M
- IPO Year
- CERS 1997
- CMPS 2020
- Fundamental
- Price
- CERS $1.70
- CMPS $4.46
- Analyst Decision
- CERS Buy
- CMPS Strong Buy
- Analyst Count
- CERS 3
- CMPS 7
- Target Price
- CERS $3.17
- CMPS $30.67
- AVG Volume (30 Days)
- CERS 1.9M
- CMPS 1.5M
- Earning Date
- CERS 10-30-2024
- CMPS 10-31-2024
- Dividend Yield
- CERS N/A
- CMPS N/A
- EPS Growth
- CERS N/A
- CMPS N/A
- EPS
- CERS N/A
- CMPS N/A
- Revenue
- CERS $176,229,000.00
- CMPS N/A
- Revenue This Year
- CERS $26.47
- CMPS N/A
- Revenue Next Year
- CERS $11.48
- CMPS N/A
- P/E Ratio
- CERS N/A
- CMPS N/A
- Revenue Growth
- CERS 14.71
- CMPS N/A
- 52 Week Low
- CERS $1.38
- CMPS $4.05
- 52 Week High
- CERS $2.59
- CMPS $12.75
- Technical
- Relative Strength Index (RSI)
- CERS 46.20
- CMPS 34.53
- Support Level
- CERS $1.63
- CMPS $4.47
- Resistance Level
- CERS $2.03
- CMPS $4.88
- Average True Range (ATR)
- CERS 0.11
- CMPS 0.43
- MACD
- CERS -0.01
- CMPS -0.01
- Stochastic Oscillator
- CERS 31.37
- CMPS 22.70
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.